変異株への有効性(第20回 厚生科学審議会予防接種・ワクチン分科会資料より抜粋) 変異株に関するQ&A(厚生労働省) 新型コロナウイルス感染症(COVID-19) 関連情報ページ(国立感染症研究所) N Engl J Med. 2021; 384:1466-1468 (Neutralizing Activity of BNT162b2-Elicited Serum) Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update(WHO) Lancet. 2021;S0140-6736(21)00947-8 (Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.) N Engl J Med. 2021;10.1056 (Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.) MedRxiv. 2021. doi: 10.1101/2021.05.22.21257658 (Effectiveness of COVID-19 vaccines against the B.1.617.2 variant.) N Engl J Med. 2021; 384:1885-1898 (Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant) N Engl J Med. 2021 July (Effectiveness of Covid-19 Vaccines against the B.1.617.2(Delta) Variant.) Vaccines highly effective against hospitalisation from Delta variant PMDAの審査報告書(ファイザー社のワクチン) PMDAの審査報告書(武田/モデルナ社のワクチン) PMDAの審査報告書(アストラゼネカ社のワクチン) ファイザー社のプレスリリース モデルナ社のプレスリリース